Zentalis Pharmaceuticals Analyst Price Targets

Zentalis Pharmaceuticals Inc

ZNTLNASDAQ

Trade with Public

$2.13

-0.11-4.91%

마지막 업데이트: Oct 16, 4:58 PM

$2.11

-0.13-5.8%

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 옵션 주식 보고서

Zentalis Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Zentalis Pharmaceuticals (ZNTL).

Price Target Range — 13 Quarters

Analyst Consensus — 10 Analysts

8Buy

2Hold

Consensus RatingBuy# Analysts10Avg. Consensus PT$9Upside to Avg. PT+303.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 5, 2026	Leerink Partners	Asthika Goonewardene	Assumes	Market Perform→Outperform	$4→$8
Sep 16, 2026	William Blair	Matt Phipps	Initiate	Outperform	—
Jul 23, 2026	Rodman & Renshaw	—	Initiate	Buy	$11
Jul 17, 2026	Mizuho	Graig Suvannavejh	Initiate	Outperform	$8
Apr 10, 2026	Guggenheim	Michael Schmidt	PT Raise	Buy	$6→$10
Mar 27, 2026	Guggenheim	Michael Schmidt	Maintained	Buy	$6
Nov 12, 2025	Morgan Stanley	Matthew Harrison	PT Cut	Equal-Weight	$8→$4
Aug 7, 2025	Wells Fargo	Derek Archila	PT Cut	Equal-Weight	$6→$5
May 15, 2025	Wedbush	Robert Driscoll	Maintained	Neutral	$4
May 15, 2025	HC Wainwright & Co.	Andres Maldonado	Maintained	Buy	$10
Mar 28, 2025	Wedbush	Robert Driscoll	Maintained	Neutral	$4
Mar 27, 2025	HC Wainwright & Co.	Andrew Fein	Maintained	Buy	$10
Mar 17, 2025	HC Wainwright & Co.	Andrew Fein	Maintained	Buy	$10
Jan 30, 2025	Wells Fargo	Derek Archila	PT Cut	Equal-Weight	$8→$6
Jan 29, 2025	HC Wainwright & Co.	Andrew Fein	PT Cut	Buy	$20→$10
Jan 28, 2025	UBS	Eliana Merle	PT Cut	Neutral	$5→$2
Nov 15, 2024	Guggenheim	Michael Schmidt	PT Cut	Buy	$12→$8
Nov 15, 2024	HC Wainwright & Co.	Andrew Fein	Maintained	Buy	$20
Sep 16, 2024	Oppenheimer	Matthew Biegler	Maintained	Outperform	$20
Aug 12, 2024	Wedbush	Robert Driscoll	Upgrade	Underperform→Neutral	$4

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Leerink Partners Assumes Zentalis Pharmaceuticals at Outperform, Raises Price Target to $8

Leerink Partners analyst Asthika Goonewardene assumes Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform rating and raises Price Target to $8.

Benzinga Newsdesk

This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales

William Blair initiates Zentalis (ZNTL) at Outperform, citing a $1.3B peak sales potential for lead cancer drug azenosertib.

Vandana Singh

PRO
William Blair Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating

William Blair analyst Matt Phipps initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform rating.

Benzinga Newsdesk

PRO
Rodman & Renshaw Initiates Coverage On Zentalis Pharmaceuticals with Buy Rating, Announces Price Target of $11

Rodman & Renshaw initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Buy rating and announces Price Target of $11.

Benzinga Newsdesk

PRO
Mizuho Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating, Announces Price Target of $8

Mizuho analyst Graig Suvannavejh initiates coverage on Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Outperform rating and announces Price Target of $8.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Zentalis Pharmaceuticals, Raises Price Target to $10

Guggenheim analyst Michael Schmidt maintains Zentalis Pharmaceuticals (NASDAQ:ZNTL) with a Buy and raises the price target from $6 to $10.

Benzinga Newsdesk

Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Leerink Partners Assumes Zentalis Pharmaceuticals at Outperform, Raises Price Target to $8

This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales

PRO
William Blair Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating

PRO
Rodman & Renshaw Initiates Coverage On Zentalis Pharmaceuticals with Buy Rating, Announces Price Target of $11

PRO
Mizuho Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating, Announces Price Target of $8

PRO
Guggenheim Maintains Buy on Zentalis Pharmaceuticals, Raises Price Target to $10

뉴스

파트너 / 기고자

벤징가 글로벌

Zentalis Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Leerink Partners Assumes Zentalis Pharmaceuticals at Outperform, Raises Price Target to $8

This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales

PRO
William Blair Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating

PRO
Rodman & Renshaw Initiates Coverage On Zentalis Pharmaceuticals with Buy Rating, Announces Price Target of $11

PRO
Mizuho Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating, Announces Price Target of $8

PRO
Guggenheim Maintains Buy on Zentalis Pharmaceuticals, Raises Price Target to $10

People Also Watch

People Also Watch

Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROLeerink Partners Assumes Zentalis Pharmaceuticals at Outperform, Raises Price Target to $8

This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales

PROWilliam Blair Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating

PRORodman & Renshaw Initiates Coverage On Zentalis Pharmaceuticals with Buy Rating, Announces Price Target of $11

PROMizuho Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating, Announces Price Target of $8

PROGuggenheim Maintains Buy on Zentalis Pharmaceuticals, Raises Price Target to $10

뉴스

파트너 / 기고자

벤징가 글로벌

Zentalis Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROLeerink Partners Assumes Zentalis Pharmaceuticals at Outperform, Raises Price Target to $8

This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales

PROWilliam Blair Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating

PRORodman & Renshaw Initiates Coverage On Zentalis Pharmaceuticals with Buy Rating, Announces Price Target of $11

PROMizuho Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating, Announces Price Target of $8

PROGuggenheim Maintains Buy on Zentalis Pharmaceuticals, Raises Price Target to $10

People Also Watch

People Also Watch

PRO
Leerink Partners Assumes Zentalis Pharmaceuticals at Outperform, Raises Price Target to $8

PRO
William Blair Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating

PRO
Rodman & Renshaw Initiates Coverage On Zentalis Pharmaceuticals with Buy Rating, Announces Price Target of $11

PRO
Mizuho Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating, Announces Price Target of $8

PRO
Guggenheim Maintains Buy on Zentalis Pharmaceuticals, Raises Price Target to $10

PRO
Leerink Partners Assumes Zentalis Pharmaceuticals at Outperform, Raises Price Target to $8

PRO
William Blair Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating

PRO
Rodman & Renshaw Initiates Coverage On Zentalis Pharmaceuticals with Buy Rating, Announces Price Target of $11

PRO
Mizuho Initiates Coverage On Zentalis Pharmaceuticals with Outperform Rating, Announces Price Target of $8

PRO
Guggenheim Maintains Buy on Zentalis Pharmaceuticals, Raises Price Target to $10